Compare Incyte Corporation (INCY) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs 22nd Century Group Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Incyte Corporation is far larger — about 15510.1× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| INCY | XXII | |
|---|---|---|
Market Cap | $23.11B | $1.49M |
Sector | Health | Technology |
52-Week High | $118.52 | $1.07K |
52-Week Low | $67.38 | $3.90 |
Enterprise Value | $19.13B | -$6.74M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
